{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:07:01Z","timestamp":1794002821092,"version":"4.8.0"},"reference-count":43,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec id=\"S0007125025000728_as1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cannabis use is linked to treatment non-adherence and relapses in psychotic disorders. Antipsychotic medication is effective for relapse prevention in primary psychoses, but its effectiveness after cannabis-induced psychosis (CIP) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125025000728_as2\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To examine the effectiveness of antipsychotic medication for relapse prevention following the first clinically diagnosed CIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125025000728_as3\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cohort of 1772 patients (84.1% men) with incident CIP was identified from the Swedish National Patient and Micro Data for Analyses of Social Insurance registers. The primary outcome was hospitalisation due to any psychotic episode. Drug use data were collected from the Prescribed Drug Register and modelled into drug use periods using the PRE2DUP method. A within-individual Cox regression model was used to study the risk of outcomes during the use of different oral or long-acting injectable (LAI) antipsychotics compared with non-use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125025000728_as4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age at first diagnosis was 26.6 years (s.d. = 8.3). Of the cohort, 1343 (75.8%) used antipsychotics and 914 (51.3%) experienced psychosis hospitalisation during the follow-up. Any antipsychotic use was associated with a decreased risk of psychosis hospitalisation (adjusted hazard ratio (aHR) 0.75; 95% CI 0.67\u20130.84). Specific antipsychotics associated with decreased risk included aripiprazole LAI (aHR 0.27; 95% CI 0.14\u20130.51), olanzapine LAI (aHR 0.28; 95% CI 0.15\u20130.53), clozapine (aHR 0.55; 95% CI 0.34\u20130.90), oral aripiprazole (aHR 0.64; 95% CI 0.45\u20130.91), antipsychotic polytherapy (aHR 0.74; 95% CI 0.63\u20130.87) and oral olanzapine (aHR 0.81; 95% CI 0.69\u20130.94).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125025000728_as5\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In particular, LAIs, clozapine and oral aripiprazole were associated with a decreased risk of psychosis relapse following CIP. Prescribers should consider using more LAIs for better treatment outcomes after CIP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.2025.72","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:30:07Z","timestamp":1746502207000},"page":"317-323","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis"],"prefix":"10.1192","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-2122","authenticated-orcid":false,"given":"Antti","family":"Mustonen","sequence":"first","affiliation":[{"name":"Tampere University"},{"name":"Karolinska Institute"},{"name":"Sein\u00e4joki Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Karolinska Institute"},{"name":"Niuvanniemi Hospital, University of Eastern Finland"},{"name":"University of Eastern Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Denissoff","sequence":"additional","affiliation":[{"name":"University of Turku"},{"name":"Turku University Hospital, Wellbeing County of South-West Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-3841","authenticated-orcid":false,"given":"Venla","family":"Ellil\u00e4","sequence":"additional","affiliation":[{"name":"University of Turku"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3218-6925","authenticated-orcid":false,"given":"Marta","family":"Di Forti","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London"},{"name":"South London and Maudsley NHS Mental Health Foundation Trust"},{"name":"National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Karolinska Institute"},{"name":"Niuvanniemi Hospital, University of Eastern Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Karolinska Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Karolinska Institute"},{"name":"Niuvanniemi Hospital, University of Eastern Finland"},{"name":"Neuroscience Center, University of Helsinki"},{"name":"Center for Psychiatry Research, Stockholm Region"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1130-9161","authenticated-orcid":false,"given":"Solja","family":"Niemel\u00e4","sequence":"additional","affiliation":[{"name":"University of Turku"},{"name":"Turku University Hospital, Wellbeing County of South-West Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"S0007125025000728_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz102"},{"key":"S0007125025000728_ref12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101217"},{"key":"S0007125025000728_ref38","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221142575"},{"key":"S0007125025000728_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30188-2"},{"key":"S0007125025000728_ref37","first-page":"CD011057","article-title":"Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse","volume":"1","author":"Temmingh","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"S0007125025000728_ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"},{"key":"S0007125025000728_ref24","first-page":"177","article-title":"A\u00a0comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a\u00a0double-blind randomized controlled trial","volume":"14","author":"Berk","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"S0007125025000728_ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-015-0140-z"},{"key":"S0007125025000728_ref33","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12623"},{"key":"S0007125025000728_ref4","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000046"},{"key":"S0007125025000728_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.11.007"},{"key":"S0007125025000728_ref15","doi-asserted-by":"publisher","DOI":"10.1017\/S003329172200229X"},{"key":"S0007125025000728_ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009888"},{"key":"S0007125025000728_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"S0007125025000728_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbad033"},{"key":"S0007125025000728_ref36","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408957"},{"key":"S0007125025000728_ref40","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040535"},{"key":"S0007125025000728_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.05.001"},{"key":"S0007125025000728_ref26","unstructured":"26 World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision (2nd edn). WHO, 2004."},{"key":"S0007125025000728_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415599846"},{"key":"S0007125025000728_ref23","doi-asserted-by":"publisher","DOI":"10.3109\/13651500009177999"},{"key":"S0007125025000728_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30233-X"},{"key":"S0007125025000728_ref17","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2011.570118"},{"key":"S0007125025000728_ref14","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719003532"},{"key":"S0007125025000728_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00363-6"},{"key":"S0007125025000728_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04928-0"},{"key":"S0007125025000728_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.07.011"},{"key":"S0007125025000728_ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.531763"},{"key":"S0007125025000728_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.06.023"},{"key":"S0007125025000728_ref22","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112561"},{"key":"S0007125025000728_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.08.005"},{"key":"S0007125025000728_ref39","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20204"},{"key":"S0007125025000728_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00231-1"},{"key":"S0007125025000728_ref31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.117"},{"key":"S0007125025000728_ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1321233"},{"key":"S0007125025000728_ref27","unstructured":"27 Norwegian Institute of Public Health. ATCDDD \u2013 Structure and Principles. Norwegian Institute of Public Health, 2022 (https:\/\/atcddd.fhi.no\/atc\/structure_and_principles\/ [cited 6 Sep 2024])."},{"key":"S0007125025000728_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2014.12126.x"},{"key":"S0007125025000728_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.03.030"},{"key":"S0007125025000728_ref1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2022.2038797"},{"key":"S0007125025000728_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae034"},{"key":"S0007125025000728_ref29","doi-asserted-by":"publisher","DOI":"10.4135\/9781412993869"},{"key":"S0007125025000728_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.3582"},{"key":"S0007125025000728_ref25","first-page":"339","article-title":"Third-generation antipsychotics and Lurasidone in the treatment of substance-induced psychoses: a\u00a0narrative review","volume":"12","author":"Ricci","year":"2024","journal-title":"Healthcare (Switzerland)"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125025000728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:35:08Z","timestamp":1785314108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125025000728\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0007125025000728"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2025.72","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}